

Intestinal cancer and the risk for other cancer in the same person

Submission date 11/06/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/06/2023	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 15/06/2023	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Disparities between tumors arising via different carcinogenetic pathways have not been studied systematically. This study evaluated the differences in the risk for non-intestinal cancer between patients with intestinal cancer originating from different carcinogenetic statuses.

Who can participate?

Adult patients with histologically confirmed colorectal cancer

What does this study involve?

This is a retrospective cohort study describing the association between intestinal and not intestinal cancer among patients with different carcinogenetic backgrounds. This retrospective European multicenter cohort study included 1706 CRC patients treated between 1986 and 2019, in three different countries.

What are the possible benefits and risks of participating?

The possible benefit is to understand the relationship between different types of cancer in the same patient. There are no risks for participants.

Where is the study run from?

Umeå University (Sweden)

When is the study starting and how long is it expected to run for?

January 2013 to March 2021

Who is funding the study?

1. Faculty of Medicine at Umeå University
2. Cancer Foundation Finland
3. Cancer Research Foundation in Northern Sweden
4. Nordic Cancer Union
5. The Northern Healthcare Regional Association

Who is the main contact?

Ioannis Gkekas (Senior Consultant Surgeon), ioannis.gkekas@umu.se (Sweden)

Contact information

Type(s)

Principal investigator

Contact name

Dr Ioannis Gkekas

ORCID ID

<https://orcid.org/0000-0002-7382-3636>

Contact details

Hoppets Gränd 8

Umeå

Sweden

90334

+46703660249

gkekasioannis@windowslive.com

Type(s)

Scientific

Contact name

Prof Ulf Gunnarsson

ORCID ID

<https://orcid.org/0000-0002-3806-2114>

Contact details

Umeå University

Faculty of medicine

Department of Surgical and Perioperative Science, Surgery,

Kungsgatan 81

Umeå

Sweden

903 30

+46706320353

ulf.gunnarsson@umu.se

Type(s)

Public

Contact name

Prof Karin Strigård

ORCID ID

<https://orcid.org/0000-0001-5838-9133>

Contact details

Umeå University
Faculty of medicine
Department of Surgical and Perioperative Science, Surgery,
Kungsgatan 81
Umeå
Sweden
903 30
0046733820772
karin.strigard@umu.se

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Sporadic deficient mismatch repair in colorectal cancer increases the risk for non-colorectal malignancy

Acronym

registerMMR

Study objectives

A higher association between sporadic deficient mismatch repair (dMMR) status and the risk of non-colorectal malignancy in patients with known colorectal cancer (CRC)

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 02/12/2014, Regional Medical Review Board in Umeå, Department of Medical Strengthening (Regional etikprövningsnämnden i Umeå Avdelningen för Medicinsk Forstkning) (Samverkanshuset, C/o Umeå Universitet, Umeå, 90187, Sweden; +46 (0)104750800; registrator@etikprovning.se), ref: 2014-371-31M

Study design

Multicenter retrospective cohort study

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Association between sporadic dMMR status and the risk of non-colorectal malignancy in patients with known colorectal cancer

Interventions

This study is a retrospective cohort describing the association between intestinal and not intestinal cancer among patients with different carcinogenetic backgrounds. This retrospective European multicenter cohort study included 1706 CRC patients treated between 1986 and 2019, in three different countries. The proficiency (pMMR) or deficiency (dMMR) of mismatch repair was determined by immunohistochemistry. Cases were analyzed for BRAFV600E mutation, and BRAF mutation cases were further analyzed for hypermethylation status in the promotor region of MLH1 in order to distinguish between sporadic and hereditary cases. Scandinavian patients were matched against their respective National Cancer Registries. Thorough scrutiny of medical files was performed for the Czech cohort to identify any non-colorectal malignancy within 20 years prior to or after the diagnosis of CRC. Poisson regression analysis was performed to identify the incidence rate of non-colorectal malignancy. For validation purposes, standardized incidence ratios (SIR) were calculated for each cancer reported, adjusted for age, year, and sex.

Intervention Type

Other

Primary outcome(s)

The risk for non-colorectal malignancy before and after this diagnosis, compared to patients with different MMR tumors is measured using Incidence Rate Ratio (IRR) in both the univariable and multivariable analyses at one timepoint

Key secondary outcome(s)

Standardized incidence ratios (SIR) are calculated for each of the cancer forms reported (patients with pMMR and dMMR separately) and adjusted for sex, year (in one-year classes), and age (in five-year classes) at one timepoint

Completion date

02/03/2021

Eligibility

Key inclusion criteria

1. Histologically confirmed CRC
2. Stage confirmed and transformed to the American Joint Committee on Cancer (AJCC) TNM classification
3. Available clinical and pathological data regarding the course of the disease and demographic data

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

1706

Key exclusion criteria

1. Patients younger than 18 years
2. Inconclusive immunohistochemical analysis (IHC) or missing data

Date of first enrolment

29/10/2015

Date of final enrolment

12/01/2021

Locations**Countries of recruitment**

Czech Republic

Finland

Sweden

Study participating centre

Umeå University hospital

Daniel Naezéns väg

Umeå

Sweden

907 37

Study participating centre

Helsinki University Hospital Department of Surgery

Haartmaninkatu 8

P.O. Box 63

Helsinki

Finland

00014

Study participating centre

Masaryk Memorial Cancer Institute

Žlutý kopec 543/7

Brno

Czech Republic

60200

Sponsor information

Organisation

Cancer Research Foundation in Northern Sweden (Cancerforskningsfonden i Norrland)

Funder(s)

Funder type

University/education

Funder Name

Medicinska fakulteten, Umeå Universitet

Alternative Name(s)

Faculty of Medicine at Umeå University, Faculty of Medicine, Umeå University, Faculty of Medicine, Medicinska fakulteten

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

Sweden

Funder Name

Syöpäsäätiö

Alternative Name(s)

Cancer Foundation Finland, Cancerstiftelsen

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Finland

Funder Name

Cancer Research Foundation in Northern Sweden

Alternative Name(s)

Northern Sweden Cancer Foundation

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Sweden

Funder Name

Nordic Cancer Union

Funder Name

Northern Healthcare Regional Association

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Ioannis Gkekas, ioannis.gkekas@umu.se. The type of data that will be shared is completely anonymization for every variable and includes sex, age, cancer stage, and type of

cancer. These data will be available immediately. Consent from participants was not required or obtained. Ethical and legal restrictions are in concordance with the ethical approval obtained.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Thesis results	Doctoral thesis; study V	21/05/2021	15/06/2023	No	No